Hofseth Biocare ASA: CORRECTION: MANDATORY NOTIFICATION OF TRADE, PRIMARY INSIDER IN HOFSETH BIOCARE ASA
January 24 2019 - 8:42AM
Hofseth AS, a 100 % owned
company of Hofseth International AS (partly, indirectly owned by
CEO Roger Hofseth and Chairman of the Board Ola Holen), has today
received 157,687 shares in Hofseth BioCare ASA ("HBC") from a
former employee of HBC, as payment for personal debt. The shares
were transferred at a price of NOK 2.42 per share.
Hofseth AS currently owns
32,245,725 shares in HBC and will, following the transaction, own a
total of 32,403,412 shares, which will represent approximately 10.9
% of the outstanding shares in Hofseth BioCare ASA. Hofseth
International AS group of companies, including Hofseth Logistics
AS, Hofseth AS, Seafood Farmers of Norway AS and Hofseth Aalesund
AS, will after the transaction hold a total of 69,881,778 shares,
representing approximately 23.7 % of the outstanding shares in
Hofseth BioCare ASA.
For further information,
please contact:
Roger Hofseth, CEO of
Hofseth BioCare ASA
Mob: +47 95147941
E-mail: rh@hofseth-as.no
Jon Olav Ødegård, CFO of
Hofseth BioCare ASA
Mob: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech
company that offers high-value ingredients and finished products
for humans and pets. The Company is founded on the core values of
sustainability, traceability and optimal utilization of natural
resources. Through an innovative hydrolysis technology, HBC is able
to preserve the quality of salmon oil, proteins and calcium,
prepared of fresh salmon off-cuts. HBC's objective is to contribute
to the efficient use of marine resources and deliver quality
products for ingredients and finished consumer products in the
nutrition market.
HBC's headquarters are located in Ålesund, Norway with branches in
Oslo, Chicago, Mumbai, Palo Alto and Tokyo. HBC is listed on Oslo
Stock Exchange Axess list with ticker "HBC". See more information
about the Company at www.hofsethbiocare.com and
ww.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire